<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516772</url>
  </required_header>
  <id_info>
    <org_study_id>CP18-02</org_study_id>
    <nct_id>NCT04516772</nct_id>
  </id_info>
  <brief_title>STAAR Visian Toric ICL Post-Approval Study</brief_title>
  <acronym>TICL-PAS</acronym>
  <official_title>Post-Approval Study of the Visian Toric Implantable Collamer Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Staar Surgical Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Staar Surgical Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the long term (i.e. 24 months) clinical&#xD;
      performance of the Visian® Toric Implantable Collamer® Lens (ICL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted at 6-8 clinical sites in the US, by surgeons qualified by&#xD;
      experience and training to implant Visian Toric ICLs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All enrolled subjects will undergo phakic eye surgery to have the STAAR Visian Toric Implantable Collamer Lens (TICL) implanted in one or both eligible eyes.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in axis orientation of the TICL</measure>
    <time_frame>18 to 24 months postoperative</time_frame>
    <description>Rotation of the TICL of less than or equal to five degrees in 90% of treated eyes between 18 and 24 months postoperative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Rotation of the TICL in treated eyes</measure>
    <time_frame>1 day, 1 week, 1 month, 3 months, 6 months, 12 months, 18 months, 24 months after surgery</time_frame>
    <description>Absolute rotation of the TICL between visits&#xD;
Absolute rotation of the TICL &lt;5 degrees, &lt;10 degrees, &lt;20 degrees, and &lt;30 degrees from intended orientation&#xD;
Absolute rotation of the TICL at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manifest refraction spherical equivalence (MRSE) and cylinder</measure>
    <time_frame>1 week, 1 month, 3 months, 6 months, 12 months, 18 months, 24 months after surgery</time_frame>
    <description>MRSE and cylinder in treated eyes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular (adverse events) AEs</measure>
    <time_frame>Through study completion, an average of 24 months</time_frame>
    <description>Incidence of AEs in treated eyes</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Myopic Astigmatism</condition>
  <arm_group>
    <arm_group_label>Visian TICL</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>STAAR Visian Toric implantable collamer lens (TICL) for the correction or reduction of myopia with astigmatism.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Visian TICL</intervention_name>
    <description>The Visian TICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.</description>
    <arm_group_label>Visian TICL</arm_group_label>
    <other_name>Visian Toric ICL</other_name>
    <other_name>TMICL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate to high myopia with astigmatism correctable with available TICL powers.&#xD;
&#xD;
          -  Stable refractive history within 0.50 D each cylinder and spherical equivalent (SE)&#xD;
             for 1 year prior to implantation.&#xD;
&#xD;
          -  Able and willing to return for scheduled follow-up examinations after surgery.&#xD;
&#xD;
          -  Able to read, understand and provide written informed consent on the Institutional&#xD;
             Review Board (IRB)-approved informed consent form (ICF) and provide authorization as&#xD;
             appropriate for local privacy regulations.&#xD;
&#xD;
          -  Other protocol-specified inclusion criteria may apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Insulin-dependent diabetes or diabetic retinopathy.&#xD;
&#xD;
          -  History of previous ocular surgery.&#xD;
&#xD;
          -  Cataract of any grade.&#xD;
&#xD;
          -  Monocular.&#xD;
&#xD;
          -  Pregnant or nursing women, or those who plan to become pregnant over the course of&#xD;
             this clinical study.&#xD;
&#xD;
          -  Other protocol-specified exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Hayashida, OD., FAAO</last_name>
    <role>Study Director</role>
    <affiliation>Vice President, Clinical and Medical Affairs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanne Egamino, PhD</last_name>
    <phone>(626) 303-7902</phone>
    <phone_ext>2215</phone_ext>
    <email>ClinicalAffairs@staar.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amber Weinmann, MSc</last_name>
    <phone>(626) 303-7902</phone>
    <phone_ext>2215</phone_ext>
    <email>ClinicalAffairs@staar.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Price Vision Group,</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP18-02 Study Coordinator</last_name>
      <phone>317-844-5530</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Solomon Eye Physicians and Surgeons/Bowie Vision Institute</name>
      <address>
        <city>Bowie</city>
        <state>Maryland</state>
        <zip>20716</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP18-02 Study Coordinator</last_name>
      <phone>301-464-1885</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vance Thompson Vision</name>
      <address>
        <city>W. Fargo</city>
        <state>North Dakota</state>
        <zip>58078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP18-02 Study Coordinator</last_name>
      <phone>701-639-2017</phone>
    </contact>
    <contact_backup>
      <phone>701-566-5628</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Eye Clinic</name>
      <address>
        <city>Brecksville</city>
        <state>Ohio</state>
        <zip>44141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP18-02 Study Coordinator</last_name>
      <phone>216-503-6535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Key-Whitman Eye Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP18-02 Study Coordinator</last_name>
      <phone>214-220-3937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hoopes Vision/Hoopes, Durrie, Rivera Research</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP18-02 Study Coordinator</last_name>
      <phone>801-988-7346</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nearsightedness</keyword>
  <keyword>phakic IOL</keyword>
  <keyword>Toric ICL</keyword>
  <keyword>TICL</keyword>
  <keyword>TMICL</keyword>
  <keyword>Visian</keyword>
  <keyword>astigmatism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

